Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Sep;104(3):811-5.
doi: 10.1007/s11060-011-0551-3. Epub 2011 Mar 4.

Leptomeningeal disease in oligodendroglial tumors: a population-based study

Gloria Roldán  1 , Jennifer Chan, Misha Eliasziw, J Gregory Cairncross, Peter A Forsyth
Affiliations

Leptomeningeal disease in oligodendroglial tumors: a population-based study

Gloria Roldán et al. J Neurooncol. 2011 Sep.

Abstract

In this population-based study, we determined the frequency and clinical characteristics of leptomeningeal disease (LMD) developing in the context of oligodendroglial tumors (oligodendrogliomas and oligoastrocytomas). LMD occurred in only 3.9% (8/204) of oligodendroglial tumors and in patients with more recurrences [mean 2.88 vs. 1.27 in LMD and non-LMD, respectively (p = 0.001)]. In contrast to LMD from systemic solid tumors, the median survival following the diagnosis of LMD in oligodendroglial tumors was surprisingly long at 22 months (95% CI 11-33 months). Treatment with oral chemotherapy seemed as effective as more aggressive treatments (e.g. repeat RT or intrathecal chemotherapy) in these patients.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Progression free survival (a) and overall survival (b) of patients with oligodendroglial tumors with and without LMD measured from the initial pathological diagnosis
Fig. 2
Fig. 2
Overall survival of 8 patients with oligodendroglial tumors from diagnosis of LMD to death
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Engelhard HH, Stelea A, Mundt A. Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment and prognosis. Surg Neurol. 2003;60:443–456. doi: 10.1016/S0090-3019(03)00167-8. - DOI - PubMed
    1. Bromberg J, Van den Bent MJ. Oligodendrogliomas: molecular biology and treatment. The Oncologist. 2009;14:155–163. doi: 10.1634/theoncologist.2008-0248. - DOI - PubMed
    1. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006;24:2707–2714. doi: 10.1200/JCO.2005.04.3414. - DOI - PubMed
    1. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organization for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24:2715–2722. doi: 10.1200/JCO.2005.04.6078. - DOI - PubMed
    1. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 2006;66:9852–9861. doi: 10.1158/0008-5472.CAN-06-1796. - DOI - PubMed

MeSH terms